These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 8095169)
21. Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer. Horiguchi J; Iino Y; Takei H; Yokoe T; Ishida T; Morishita Y Oncology; 1994; 51(1):47-51. PubMed ID: 7903441 [TBL] [Abstract][Full Text] [Related]
23. [Development of sandwich radioimmunometric assay for serum c-erbB-2 oncogene product and its significance in diagnosing breast carcinoma]. Yu FZ; Sugano K; Ohkura H; Mori S Rinsho Byori; 1991 Oct; 39(10):1087-92. PubMed ID: 1684826 [TBL] [Abstract][Full Text] [Related]
24. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762 [TBL] [Abstract][Full Text] [Related]
25. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. Gusterson BA; Gelber RD; Goldhirsch A; Price KN; Säve-Söderborgh J; Anbazhagan R; Styles J; Rudenstam CM; Golouh R; Reed R J Clin Oncol; 1992 Jul; 10(7):1049-56. PubMed ID: 1351538 [TBL] [Abstract][Full Text] [Related]
26. [Clinical study of serum ErbB-2 protein using sandwich radioimmunometric assay (ErbB-2 IRMA 'Eiken')]. Sugano K; Kawai T; Ishii M; Koyama H; Kitajima M; Kasumi F; Demura R; Nakayama T; Okabe H; Mori S Gan To Kagaku Ryoho; 1994 Jul; 21(8):1245-53. PubMed ID: 7913312 [TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human breast cancer. Schimmelpenning H; Eriksson ET; Falkmer UG; Rutqvist LE; Johansson H; Fallenius A; Auer GU Eur J Surg Oncol; 1992 Dec; 18(6):530-7. PubMed ID: 1362164 [TBL] [Abstract][Full Text] [Related]
29. [Study of c-erbB-2 expression in breast neoplasms]. Ye F Zhonghua Bing Li Xue Za Zhi; 1993 Apr; 22(2):104-6. PubMed ID: 8104720 [TBL] [Abstract][Full Text] [Related]
30. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. Shimizu C; Fukutomi T; Tsuda H; Akashi-Tanaka S; Watanabe T; Nanasawa T; Sugihara K J Surg Oncol; 2000 Jan; 73(1):17-20. PubMed ID: 10649273 [TBL] [Abstract][Full Text] [Related]
31. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144 [TBL] [Abstract][Full Text] [Related]
32. Construction of immunoradiometric assay for circulating c-erbB-2 protooncogene product in advanced breast cancer patients. Hosono M; Saga T; Sakahara H; Kobayashi H; Shirato M; Endo K; Yamamoto T; Akiyama T; Toyoshima K; Konishi J Jpn J Cancer Res; 1993 Feb; 84(2):147-52. PubMed ID: 8096502 [TBL] [Abstract][Full Text] [Related]
33. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956 [TBL] [Abstract][Full Text] [Related]
34. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. Molina R; Jo J; Zanón G; Filella X; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM Br J Cancer; 1996 Oct; 74(7):1126-31. PubMed ID: 8855986 [TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898 [TBL] [Abstract][Full Text] [Related]
36. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins. Zhang GJ; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S Jpn J Clin Oncol; 1997 Dec; 27(6):371-7. PubMed ID: 9437997 [TBL] [Abstract][Full Text] [Related]
37. [Expression and clinical significance of KNSL4 in breast cancer]. Feng YM; Wan YF; Li XQ; Cao XC; Li X Ai Zheng; 2006 Jun; 25(6):744-8. PubMed ID: 16764773 [TBL] [Abstract][Full Text] [Related]
38. [Clinical evaluation of ErbB-2 protein in tissue extract using an enzyme immuno assay (ErbB-2 EIA "Nichirei")]. Sugano K; Kitajima M; Ishii M; Koyama H; Kasumi F; Demura R; Mori S; Ohkura H Gan To Kagaku Ryoho; 1994 Sep; 21(12):1957-66. PubMed ID: 7916182 [TBL] [Abstract][Full Text] [Related]
39. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. Leitzel K; Teramoto Y; Konrad K; Chinchilli VM; Volas G; Grossberg H; Harvey H; Demers L; Lipton A J Clin Oncol; 1995 May; 13(5):1129-35. PubMed ID: 7738618 [TBL] [Abstract][Full Text] [Related]
40. Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. Andersen TI; Paus E; Nesland JM; McKenzie SJ; Børresen AL Acta Oncol; 1995; 34(4):499-504. PubMed ID: 7605658 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]